KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $5.7 million.

  • CRISPR Therapeutics AG's Depreciation & Amortization (CF) rose 1691.45% to $5.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $19.5 million, marking a year-over-year increase of 114.23%. This contributed to the annual value of $19.5 million for FY2025, which is 114.23% up from last year.
  • According to the latest figures from Q4 2025, CRISPR Therapeutics AG's Depreciation & Amortization (CF) is $5.7 million, which was up 1691.45% from $4.4 million recorded in Q3 2025.
  • CRISPR Therapeutics AG's 5-year Depreciation & Amortization (CF) high stood at $7.3 million for Q2 2022, and its period low was $2.7 million during Q1 2021.
  • In the last 5 years, CRISPR Therapeutics AG's Depreciation & Amortization (CF) had a median value of $4.9 million in 2023 and averaged $5.0 million.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Depreciation & Amortization (CF) soared by 14399.84% in 2021, and later crashed by 3175.13% in 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Depreciation & Amortization (CF) (Quarter) stood at $6.3 million in 2021, then decreased by 6.63% to $5.8 million in 2022, then decreased by 16.18% to $4.9 million in 2023, then dropped by 1.18% to $4.8 million in 2024, then grew by 16.91% to $5.7 million in 2025.
  • Its Depreciation & Amortization (CF) was $5.7 million in Q4 2025, compared to $4.4 million in Q3 2025 and $4.6 million in Q2 2025.